NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.92 USD
-1.30 (-8.54%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $13.94 +0.02 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
NeoGenomics, Inc. [NEO]
Reports for Purchase
Showing records 81 - 100 ( 132 total )
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
The Last CMS Shoe Has Dropped, Operating Leverage Ahead
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Covances Acquisition Throws a Wrench in NEOs Plans, Selling Overdone
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Continued Test Menu Expansion Bolsters Confidence in Our 2015 Estimates
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Slowly, But Surely Hacking Away at Foundation Medicine
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Volume and Impending PCa-Test Drives Urology-Focused Management Addition
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
PCa Test Launch During 1H15 Set to Bolster Robust Core Business
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D